SS-31 (Elamipretide) Research Guide Ireland

Overview

SS-31, known clinically as Elamipretide (also referenced in earlier literature as Bendavia or MTP-131), is a synthetic tetrapeptide belonging to the Szeto-Schiller family of mitochondria-targeted compounds, named after its originators Hazel H. Szeto and Peter Schiller. Unlike growth hormone secretagogue peptides, SS-31 is built on an alternating aromatic-cationic amino acid motif that allows it to concentrate selectively in the inner mitochondrial membrane, where it binds cardiolipin — a phospholipid found almost exclusively in that membrane and essential to maintaining the folded cristae structure that supports efficient electron transport chain (ETC) function. Elamipretide has since been developed clinically by Stealth BioTherapeutics and carries one of the more extensive real human trial programmes among mitochondria-targeted research peptides, spanning Barth syndrome, primary mitochondrial myopathy, and dry age-related macular degeneration (dry AMD). Despite this substantial clinical investment across multiple Phase 2 and Phase 3 trials, it is important to state plainly that Elamipretide has not achieved FDA or EMA approval for any indication, and several of its late-stage trials did not meet their primary endpoints. This guide is for educational and research purposes only. Not medical advice.

Clinical & Research Status

Evidence Type	Status
Human RCT	✔
Observational	✔
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗

Multiple real Phase 2/3 human randomised controlled trials have been conducted, alongside observational extension studies, animal models, and in vitro cardiolipin-binding work. No regulatory body has approved Elamipretide for any indication to date, despite this unusually deep trial record for a research peptide.

Mechanism of Action

SS-31/Elamipretide works fundamentally differently from GH-secretagogue peptides such as Ipamorelin or CJC-1295 — it does not act on a cell-surface receptor to trigger a hormonal cascade. Instead, its aromatic-cationic structure allows it to accumulate in mitochondria and bind directly to cardiolipin on the inner mitochondrial membrane. This interaction is thought to stabilise the folded cristae architecture of the membrane, which in turn supports more efficient assembly and function of electron transport chain complexes. By protecting cristae structure and ETC efficiency, research models suggest SS-31 can reduce electron leakage and the resulting production of reactive oxygen species (ROS), while supporting more consistent ATP synthesis. This positions the compound as a mitochondria-targeted bioenergetics and antioxidant candidate rather than a hormone-modulating peptide, which is why its research programme centres on conditions with a clear mitochondrial or oxidative-stress component — muscle disease, cardiac tissue, and retinal degeneration — rather than growth, body composition, or metabolic peptide-typical endpoints.

Research Areas & Reported Effects

Mitochondrial Bioenergetics & Cristae Structure

The foundational body of SS-31 research is preclinical and in vitro work demonstrating cardiolipin binding, cristae stabilisation, and improved electron transport chain coupling in isolated mitochondria and cell models. These studies form the mechanistic basis for all later clinical trial programmes and consistently show reduced ROS output alongside preserved ATP-generating capacity under stress conditions.

Barth Syndrome Research (TAZPOWER Trial)

The TAZPOWER trial (NCT02653548) investigated Elamipretide in patients with Barth syndrome, a rare genetic mitochondrial cardiomyopathy. The trial reported improvements in 6-minute walk test distance and some functional and patient-reported measures. However, results were mixed and nuanced — the trial did not cleanly meet all of its co-primary endpoints, and this should be represented honestly rather than as an unambiguous success.

Primary Mitochondrial Myopathy Research (MMPOWER / MMPOWER-3)

The MMPOWER and MMPOWER-3 trials examined Elamipretide in primary mitochondrial myopathy. MMPOWER-3, a Phase 3 trial, is a notable negative result in the peptide's research record: it did not meet its primary endpoint of 6-minute walk distance versus placebo. This is an important and real finding that should not be omitted — it represents one of the clearest signals that, despite strong preclinical rationale, clinical efficacy in this population was not demonstrated at the Phase 3 level.

Ophthalmic Research in Dry AMD

The ReCLAIM and ReCLAIM-2 trials explored intravitreal and subretinal Elamipretide in dry age-related macular degeneration, specifically geographic atrophy. Results were mixed — some anatomical benefit signals were reported, but these were not uniformly matched by functional visual outcome improvements. Elamipretide has also appeared in ophthalmology literature discussing Leber hereditary optic neuropathy, though this remains exploratory.

Research Data Summary

Study / Model	Reported Effect
Preclinical mitochondrial function studies (animal / cell models)	Positive signals for cardiolipin binding, cristae stabilisation, and reduced ROS production supporting improved bioenergetics.
TAZPOWER Trial (Barth syndrome, NCT02653548)	Some improvement in 6-minute walk test and functional measures; did not cleanly meet all co-primary endpoints — mixed result.
MMPOWER-3 Trial (Phase 3, primary mitochondrial myopathy)	Did not significantly separate from placebo on 6-minute walk distance — a negative/null primary endpoint result.
ReCLAIM-2 Trial (dry AMD, geographic atrophy)	Mixed outcomes — some anatomical benefit signals reported without uniform functional visual improvement.

Stack Combinations Studied

• SS-31 + MOTS-c → Research rationale: Both are mitochondria-associated peptides; researchers have explored combining a cardiolipin-stabilising compound (SS-31) with a mitochondrial-derived peptide implicated in cellular energy signalling (MOTS-c) to examine complementary effects on cellular bioenergetics.
• SS-31 + antioxidant compounds (e.g., CoQ10 analogues) → Research rationale: Investigated in preclinical settings for combined mitochondrial-protective and ROS-scavenging effects, given SS-31's role in reducing electron transport chain leakage.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
Low-Range Trial Reference	~0.25 mg/kg/hr (acute IV, trial context)	Single infusion / acute study window	As per acute trial protocol	Acute mitochondrial function and pharmacokinetic study designs.
Standard Trial Reference	~40 mg (fixed subcutaneous dose, chronic trial context)	Weeks to months (per MMPOWER/TAZPOWER trial design)	Once daily	Chronic mitochondrial myopathy and Barth syndrome trial protocols.
Advanced / Ophthalmic Trial Reference	Intravitreal / subretinal micro-dosing (ReCLAIM trial context)	Per ReCLAIM/ReCLAIM-2 trial schedule	As per ophthalmic trial protocol	Dry AMD / geographic atrophy trial designs.

Figures above are drawn from published trial-context dosing (TAZPOWER, MMPOWER, MMPOWER-3, ReCLAIM, ReCLAIM-2) and are presented purely as historical trial reference, not as a recommendation.

Observed Side Effects in Research

• Injection site reactions / erythema (the most commonly reported adverse event across chronic subcutaneous trials)
• Mild gastrointestinal discomfort (reported in some trial participants)
• Transient headache (infrequent)

Across the TAZPOWER, MMPOWER, and ReCLAIM trial programmes, Elamipretide was generally reported as well-tolerated with a relatively clean safety profile. No major severe adverse event pattern emerged in the trials cited, though injection site reactions were a consistent and common finding.

Compound Data

CAS Number

736992-21-5

Molecular Formula

C₄₀H₆₀N₁₀O₇

Molecular Weight

Approximately 807.98 g/mol (free base; salt forms vary)

Half-Life

Short (minutes); typically administered by daily subcutaneous injection in trials

Synonyms

Elamipretide, Bendavia, MTP-131

Research Classification

Mitochondria-Targeted Tetrapeptide, Cardiolipin-Binding Compound, Szeto-Schiller (SS) Peptide

Scientific References

• [Szeto HH. 2014] — First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. — British Journal of Pharmacology — [Review / Mechanism]
• [Thompson WR et al. 2021] — Elamipretide in Barth syndrome: safety and efficacy findings from the TAZPOWER trial. — Genetics in Medicine — [Human RCT]
• [Karaa A et al. 2021] — Elamipretide in mitochondrial disease: an open-label long-term extension study and MMPOWER-3 outcomes. — Neurology — [Human RCT / Phase 3]

This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.